Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses

Chun Jen Liu; Wan Long Chuang; Chuan Mo Lee; Ming Lung Yu; Sheng Nan Lu; Shun Sheng Wu; Li Ying Liao; Chi Ling Chen; Hsing Tao Kuo; You Chen Chao; Shui Yi Tung; Sien Sing Yang; Jia Horng Kao; Chen Hua Liu; Wei Wen Su; Chih Lin Lin; Yung Ming Jeng; Pei Jer Chen; Ding Shinn Chen

doi:10.1053/j.gastro.2008.10.049

Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses

Chun Jen Liu, Wan Long Chuang, Chuan Mo Lee, Ming Lung Yu, Sheng Nan Lu, Shun Sheng Wu, Li Ying Liao, Chi Ling Chen, Hsing Tao Kuo, You Chen Chao, Shui Yi Tung, Sien Sing Yang, Jia Horng Kao, Chen Hua Liu, Wei Wen Su, Chih Lin Lin, Yung Ming Jeng, Pei Jer Chen, Ding Shinn Chen^*

^*Corresponding author for this work

Research output: Contribution to journal › Journal Article › peer-review

193 Scopus citations

Abstract

Background & Aims: Dual chronic infection with hepatitis C virus (HCV) and hepatitis B virus (HBV) is common in areas endemic for either virus. Combination therapy with ribavirin and pegylated interferon (peginterferon) is the standard of care for patients with HCV monoinfection. We investigated the effects of combination therapy in patients infected with both HBV and HCV (genotypes 1, 2, or 3). Methods: The study included 321 Taiwanese patients with active HCV infection; 161 also tested positive for hepatitis B surface antigen (HBsAg) and 160 were HBsAg-negative (controls). Patients with HCV genotype 1 infection received peginterferon alfa-2a (180 μg) weekly for 48 weeks and ribavirin (1000-1200 mg) daily. Patients with HCV genotypes 2 or 3 received peginterferon alfa-2a weekly for 24 weeks and ribavirin (800 mg) daily. At 24 weeks posttreatment, patient samples were examined for a sustained virologic response (SVR) against HCV (serum HCV levels decreased to <25 IU/mL). Results: In patients with HCV genotype 1 infection, the SVR was 72.2% in dually infected patients vs 77.3% in monoinfected patients after treatment. For patients with HCV genotype 2/3 infections, the SVR values were 82.8% and 84.0%, respectively, after treatment. Serum HBV DNA eventually appeared in 36.3% of 77 dual-infected patients with undetectable pretreatment levels of HBV DNA; this was not accompanied by significant hepatitis. Posttreatment HBsAg clearance was observed in 11.2% of 161 dual-infected patients. Conclusions: Combination therapy with peginterferon alfa-2a and ribavirin is equally effective in patients with HCV monoinfection and in those with dual chronic HCV/HBV infection.

Original language	English
Pages (from-to)	496-504.e3
Journal	Gastroenterology
Volume	136
Issue number	2
DOIs	https://doi.org/10.1053/j.gastro.2008.10.049
State	Published - 02 2009
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1053/j.gastro.2008.10.049

Cite this

Liu, C. J., Chuang, W. L., Lee, C. M., Yu, M. L., Lu, S. N., Wu, S. S., Liao, L. Y., Chen, C. L., Kuo, H. T., Chao, Y. C., Tung, S. Y., Yang, S. S., Kao, J. H., Liu, C. H., Su, W. W., Lin, C. L., Jeng, Y. M., Chen, P. J., & Chen, D. S. (2009). Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses. Gastroenterology, 136(2), 496-504.e3. https://doi.org/10.1053/j.gastro.2008.10.049

@article{d8b3ecb49d824d57a11f2547677fb318,

title = "Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses",

abstract = "Background \& Aims: Dual chronic infection with hepatitis C virus (HCV) and hepatitis B virus (HBV) is common in areas endemic for either virus. Combination therapy with ribavirin and pegylated interferon (peginterferon) is the standard of care for patients with HCV monoinfection. We investigated the effects of combination therapy in patients infected with both HBV and HCV (genotypes 1, 2, or 3). Methods: The study included 321 Taiwanese patients with active HCV infection; 161 also tested positive for hepatitis B surface antigen (HBsAg) and 160 were HBsAg-negative (controls). Patients with HCV genotype 1 infection received peginterferon alfa-2a (180 μg) weekly for 48 weeks and ribavirin (1000-1200 mg) daily. Patients with HCV genotypes 2 or 3 received peginterferon alfa-2a weekly for 24 weeks and ribavirin (800 mg) daily. At 24 weeks posttreatment, patient samples were examined for a sustained virologic response (SVR) against HCV (serum HCV levels decreased to <25 IU/mL). Results: In patients with HCV genotype 1 infection, the SVR was 72.2\% in dually infected patients vs 77.3\% in monoinfected patients after treatment. For patients with HCV genotype 2/3 infections, the SVR values were 82.8\% and 84.0\%, respectively, after treatment. Serum HBV DNA eventually appeared in 36.3\% of 77 dual-infected patients with undetectable pretreatment levels of HBV DNA; this was not accompanied by significant hepatitis. Posttreatment HBsAg clearance was observed in 11.2\% of 161 dual-infected patients. Conclusions: Combination therapy with peginterferon alfa-2a and ribavirin is equally effective in patients with HCV monoinfection and in those with dual chronic HCV/HBV infection.",

author = "Liu, \{Chun Jen\} and Chuang, \{Wan Long\} and Lee, \{Chuan Mo\} and Yu, \{Ming Lung\} and Lu, \{Sheng Nan\} and Wu, \{Shun Sheng\} and Liao, \{Li Ying\} and Chen, \{Chi Ling\} and Kuo, \{Hsing Tao\} and Chao, \{You Chen\} and Tung, \{Shui Yi\} and Yang, \{Sien Sing\} and Kao, \{Jia Horng\} and Liu, \{Chen Hua\} and Su, \{Wei Wen\} and Lin, \{Chih Lin\} and Jeng, \{Yung Ming\} and Chen, \{Pei Jer\} and Chen, \{Ding Shinn\}",

year = "2009",

month = feb,

doi = "10.1053/j.gastro.2008.10.049",

language = "英语",

volume = "136",

pages = "496--504.e3",

journal = "Gastroenterology",

issn = "0016-5085",

publisher = "W.B. Saunders",

number = "2",

}

Liu, CJ, Chuang, WL, Lee, CM, Yu, ML, Lu, SN, Wu, SS, Liao, LY, Chen, CL, Kuo, HT, Chao, YC, Tung, SY, Yang, SS, Kao, JH, Liu, CH, Su, WW, Lin, CL, Jeng, YM, Chen, PJ & Chen, DS 2009, 'Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses', Gastroenterology, vol. 136, no. 2, pp. 496-504.e3. https://doi.org/10.1053/j.gastro.2008.10.049

TY - JOUR

T1 - Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses

AU - Liu, Chun Jen

AU - Chuang, Wan Long

AU - Lee, Chuan Mo

AU - Yu, Ming Lung

AU - Lu, Sheng Nan

AU - Wu, Shun Sheng

AU - Liao, Li Ying

AU - Chen, Chi Ling

AU - Kuo, Hsing Tao

AU - Chao, You Chen

AU - Tung, Shui Yi

AU - Yang, Sien Sing

AU - Kao, Jia Horng

AU - Liu, Chen Hua

AU - Su, Wei Wen

AU - Lin, Chih Lin

AU - Jeng, Yung Ming

AU - Chen, Pei Jer

AU - Chen, Ding Shinn

PY - 2009/2

Y1 - 2009/2

N2 - Background & Aims: Dual chronic infection with hepatitis C virus (HCV) and hepatitis B virus (HBV) is common in areas endemic for either virus. Combination therapy with ribavirin and pegylated interferon (peginterferon) is the standard of care for patients with HCV monoinfection. We investigated the effects of combination therapy in patients infected with both HBV and HCV (genotypes 1, 2, or 3). Methods: The study included 321 Taiwanese patients with active HCV infection; 161 also tested positive for hepatitis B surface antigen (HBsAg) and 160 were HBsAg-negative (controls). Patients with HCV genotype 1 infection received peginterferon alfa-2a (180 μg) weekly for 48 weeks and ribavirin (1000-1200 mg) daily. Patients with HCV genotypes 2 or 3 received peginterferon alfa-2a weekly for 24 weeks and ribavirin (800 mg) daily. At 24 weeks posttreatment, patient samples were examined for a sustained virologic response (SVR) against HCV (serum HCV levels decreased to <25 IU/mL). Results: In patients with HCV genotype 1 infection, the SVR was 72.2% in dually infected patients vs 77.3% in monoinfected patients after treatment. For patients with HCV genotype 2/3 infections, the SVR values were 82.8% and 84.0%, respectively, after treatment. Serum HBV DNA eventually appeared in 36.3% of 77 dual-infected patients with undetectable pretreatment levels of HBV DNA; this was not accompanied by significant hepatitis. Posttreatment HBsAg clearance was observed in 11.2% of 161 dual-infected patients. Conclusions: Combination therapy with peginterferon alfa-2a and ribavirin is equally effective in patients with HCV monoinfection and in those with dual chronic HCV/HBV infection.

AB - Background & Aims: Dual chronic infection with hepatitis C virus (HCV) and hepatitis B virus (HBV) is common in areas endemic for either virus. Combination therapy with ribavirin and pegylated interferon (peginterferon) is the standard of care for patients with HCV monoinfection. We investigated the effects of combination therapy in patients infected with both HBV and HCV (genotypes 1, 2, or 3). Methods: The study included 321 Taiwanese patients with active HCV infection; 161 also tested positive for hepatitis B surface antigen (HBsAg) and 160 were HBsAg-negative (controls). Patients with HCV genotype 1 infection received peginterferon alfa-2a (180 μg) weekly for 48 weeks and ribavirin (1000-1200 mg) daily. Patients with HCV genotypes 2 or 3 received peginterferon alfa-2a weekly for 24 weeks and ribavirin (800 mg) daily. At 24 weeks posttreatment, patient samples were examined for a sustained virologic response (SVR) against HCV (serum HCV levels decreased to <25 IU/mL). Results: In patients with HCV genotype 1 infection, the SVR was 72.2% in dually infected patients vs 77.3% in monoinfected patients after treatment. For patients with HCV genotype 2/3 infections, the SVR values were 82.8% and 84.0%, respectively, after treatment. Serum HBV DNA eventually appeared in 36.3% of 77 dual-infected patients with undetectable pretreatment levels of HBV DNA; this was not accompanied by significant hepatitis. Posttreatment HBsAg clearance was observed in 11.2% of 161 dual-infected patients. Conclusions: Combination therapy with peginterferon alfa-2a and ribavirin is equally effective in patients with HCV monoinfection and in those with dual chronic HCV/HBV infection.

UR - https://www.scopus.com/pages/publications/84984585800

U2 - 10.1053/j.gastro.2008.10.049

DO - 10.1053/j.gastro.2008.10.049

M3 - 文章

C2 - 19084016

AN - SCOPUS:84984585800

SN - 0016-5085

VL - 136

SP - 496-504.e3

JO - Gastroenterology

JF - Gastroenterology

IS - 2

ER -

Peginterferon Alfa-2a Plus Ribavirin for the Treatment of Dual Chronic Infection With Hepatitis B and C Viruses

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this